Pregabalin: a new approach to treatment of the dysautonomic crisis

Pediatrics. 2009 Aug;124(2):743-6. doi: 10.1542/peds.2008-3318. Epub 2009 Jul 20.

Abstract

Nausea and dysautonomic crises severely limit function and quality of life for a large number of individuals with familial dysautonomia. We treated a small cohort of 15 patients with familial dysautonomia who suffered frequent dysautonomic crises with pregabalin. Nausea and overt crises markedly decreased in 13 (87%) of these patients and the overall assessments of benefit were extremely favorable, suggesting that pregabalin may be a potentially useful therapeutic agent for this disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Carrier Proteins / genetics
  • Child
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Dysautonomia, Familial / diagnosis
  • Dysautonomia, Familial / drug therapy*
  • Dysautonomia, Familial / genetics
  • Female
  • Humans
  • Male
  • Pregabalin
  • Transcriptional Elongation Factors
  • Young Adult
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Anticonvulsants
  • Carrier Proteins
  • Elp1 protein, human
  • Transcriptional Elongation Factors
  • Pregabalin
  • gamma-Aminobutyric Acid